Subtype
WHO Grade 3 Glioma
CI-CAN-00007116Explore in graph →
57 active trials1 approved drugs9 evidence items
- NCIt
- C127816
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007116Explore in graph →
Clinical trials
258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (53)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07448480 | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas(GLIOTARG) | active not recruiting | — | 1,000 | Blokhin's Russian Cancer Research CenterOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT03389230 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | active not recruiting | Phase 1 | 29 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03251027 | Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma | active not recruiting | N/A | 100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | recruiting | Early Phase 1 | 12 | Oliver JonasOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT06975332 | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression | recruiting | N/A | 35 | Medical University of WarsawOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06283927 | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)(RECSUR) | recruiting | — | 464 | Jasper GerritsenOTHER | 5 | Feb 28, 2024 | clinicaltrials |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)(SUPRAMAX) | recruiting | — | 784 | Jasper GerritsenOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06273176 | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma(RECMAP) | recruiting | — | 225 | Erasmus Medical CenterOTHER | 5 | Feb 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2026source: clinicaltrials